Abstract: The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
June 27, 2017
Assignees:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, XERIS PHARMACEUTICALS, INC.
Inventors:
Steven Prestrelski, Wei-Jie Fang, John F. Carpenter, John Kinzell
Abstract: Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.
Abstract: Disclosed is a method of making ?-polypeptides. The method includes polymerizing ?-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product ?-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
June 20, 2017
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Shannon S. Stahl, Samuel H. Gellman, Sarah E. Lee, Mehmet F. Ilker, Bernard Weisblum, Denis Kissounko
Abstract: The present invention includes an anisotropic scaffold, which is prepared by electrospinning a solution of matrix material upon a textile template. The present invention further includes a method of preparing such scaffold. The anisotropic scaffold of the invention finds use in tissue engineering and regenerative medicine.
Type:
Grant
Filed:
May 23, 2011
Date of Patent:
June 6, 2017
Assignees:
Drexel University, Philadelphia University
Inventors:
Peter I. Lelkes, H. Gozde Senel, David Brookstein, Muthu Govindaraj
Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
May 30, 2017
Assignee:
Allergan, Inc.
Inventors:
Jacob F. Pollock, Lauren E. Kokai, Cunqi Cui, Xiaojie Yu, Dennis E. Van Epps, Darin J. Messina
Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
May 30, 2017
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Sandra O'Connor, Sophie Sun, Gaauri Naik
Abstract: The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.
Type:
Grant
Filed:
January 3, 2014
Date of Patent:
May 30, 2017
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Sung Youb Jung, Sang Youn Hwang, In Young Choi, Sung Hee Park, Se Chang Kwon
Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
Type:
Grant
Filed:
October 30, 2015
Date of Patent:
May 23, 2017
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Masanori Onda, Wenhai Liu
Abstract: The present invention refers to a cosmetic composition of the oil-in-glycol type comprising (a) at least one sucrose non-ionic surfactant or derivatives thereof, (b) at least one fatty alcohol, (c) at least one glycol and (d) at least one ingredient selected from aminoacid and/or peptide, as well as associated uses, products and methods. The composition of the invention is capable of restoring the cutaneous barrier, reorganizing the lipidic layer of the stratum corneum in orthorhombic, conceding hydration, renewal and cellular energization in the long run. In a particular embodiment, said composition can be used simultaneously as an emulsifying system for preparing cosmetic products, for example, in the preparation of creams, lotions, etc.
Type:
Grant
Filed:
May 24, 2011
Date of Patent:
May 23, 2017
Assignee:
ISP INVESTMENTS LLC
Inventors:
Alexandra Bazito, Maria Regina Bartuccio Raponi, Nelson Luis Perassinoto, Liliana Calore Brenner
Abstract: The present invention described herein relates to compositions that interact with molecules that suppress the immune system. More specifically, embodiments described herein concern the discovery, manufacture, and use of compositions that remove immunosuppression the immune system by binding to immunoregulatory peptides that interact with receptors on immune cells, compositions the can stimulate immune cells, and compositions that are cytotoxic to tumor cells.
Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.
Type:
Grant
Filed:
April 22, 2016
Date of Patent:
May 16, 2017
Assignee:
XERIS PHARMACEUTICALS, INC.
Inventors:
Steven Prestrelski, Michael Sandoval, Martin Donovan
Abstract: Disclosed is a composition for parenteral administration comprising a glucagon peptide which has been dried in a non-volatile glycine buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer, wherein the pH memory is between 2.5 to 3.5, an aprotic polar solvent, wherein the peptide is solubilized in the aprotic polar solvent, and wherein the aprotic polar solvent is dimethyl sulfoxide (DMSO), trehalose, glycine, and optionally hydrochloric acid, wherein the moisture content of the composition is less than 5 wt. %.
Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Abstract: The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics.
Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Type:
Grant
Filed:
November 14, 2013
Date of Patent:
May 2, 2017
Assignee:
ENDOCYTE, INC.
Inventors:
Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
Abstract: In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides.
Type:
Grant
Filed:
July 9, 2014
Date of Patent:
April 11, 2017
Assignees:
UNIVERSITY OF HOUSTON, RENSSELAER POLYTECHNIC INSTITUTE
Abstract: Disclosed herein are cargo carrying nanoparticles and pharmaceutical formulations thereof. The cargo carrying nanoparticles can self-assemble from cargo molecule subunits and/or targeting subunits. The cargo carrying molecules can be configured to induce macropinocytosis in a cell when a targeting moiety specifically binds a binding partner on the surface of a cell. The pharmaceutical formulations containing the cargo carrying nanoparticles disclosed herein can be administered to a patient for the treatment or prevention of cancer.